Literature DB >> 29549545

Becoming an Evidence-Based Practitioner.

Mark M Lowis1, Jennifer Harrison2, Steve Wiland3.   

Abstract

Mental health and substance use disorders co-occur frequently, and are associated with poorer outcomes in life domains including housing, employment, health, and recovery. Finding evidence-based interventions for engagement and recovery can be a challenge for practitioners and organizations, as it involves accepting new interventions, and then implementing and measuring the results. However, practitioners frequently use their opinions or non-generalizable experiences rather than evidence-based findings to guide their practice. Medication-assisted therapy programs, especially for individuals with co-occurring mental health and substance use disorders, is an area of treatment where there are solid evidence-based outcome findings and where, nonetheless, many practitioners continue to use less-, or non-effective treatment approaches. Conflict between groups of staff using two different approaches can have serious negative impact on treatment outcome. These can be effectively addressed through a combination of education and interventions aimed at resolving intra-staff conflict.

Keywords:  Co-occurring disorders; Evidence-based practitioner; Motivational approaches

Mesh:

Year:  2018        PMID: 29549545     DOI: 10.1007/s10597-018-0261-9

Source DB:  PubMed          Journal:  Community Ment Health J        ISSN: 0010-3853


  14 in total

1.  Schizophrenia and co-occurring substance use disorder.

Authors:  Alan I Green; Robert E Drake; Mary F Brunette; Douglas L Noordsy
Journal:  Am J Psychiatry       Date:  2007-03       Impact factor: 18.112

2.  Facilitating factors in implementing four evidence-based practices: reports from addiction treatment staff.

Authors:  Maryann Amodeo; Lena Lundgren; Clelia Fernanda Beltrame; Deborah Chassler; Alexander Cohen; Melinda D'Ippolito
Journal:  Subst Use Misuse       Date:  2013-06-10       Impact factor: 2.164

3.  Barriers to implementing evidence-based practices in addiction treatment programs: comparing staff reports on Motivational Interviewing, Adolescent Community Reinforcement Approach, Assertive Community Treatment, and Cognitive-behavioral Therapy.

Authors:  M Amodeo; L Lundgren; A Cohen; D Rose; D Chassler; C Beltrame; M D'Ippolito
Journal:  Eval Program Plann       Date:  2011-03-21

Review 4.  Comorbidity of psychiatric and substance use disorders in the United States: current issues and findings from the NESARC.

Authors:  Deborah Hasin; Bari Kilcoyne
Journal:  Curr Opin Psychiatry       Date:  2012-05       Impact factor: 4.741

5.  Integrated Dual Disorder Treatment Implementation in a Large State Sample.

Authors:  Jennifer Harrison; Amy Curtis; Linwood Cousins; Jessaca Spybrook
Journal:  Community Ment Health J       Date:  2016-05-28

Review 6.  Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence.

Authors:  Laura Amato; Silvia Minozzi; Marina Davoli; Simona Vecchi
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

7.  Exploration of the comorbidity of alcohol use disorders and mental health disorders among inpatients presenting to all hospitals in New South Wales, Australia.

Authors:  Harry Man Xiong Lai; Thiagarajan Sitharthan; Qi Rong Huang
Journal:  Subst Abus       Date:  2012       Impact factor: 3.716

8.  The impact of substance use disorders on the course of schizophrenia--a 15-year follow-up study: dual diagnosis over 15 years.

Authors:  Lasse M Schmidt; Moten Hesse; Jørn Lykke
Journal:  Schizophr Res       Date:  2011-05-18       Impact factor: 4.939

Review 9.  Research on the diffusion of evidence-based treatments within substance abuse treatment: a systematic review.

Authors:  Bryan R Garner
Journal:  J Subst Abuse Treat       Date:  2008-11-12

10.  American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use.

Authors:  Kyle Kampman; Margaret Jarvis
Journal:  J Addict Med       Date:  2015 Sep-Oct       Impact factor: 3.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.